We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
-9.94%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$218M
AUM Growth
-$1.85M
Cap. Flow
+$19.9M
Cap. Flow %
9.15%
Top 10 Hldgs %
83.54%
Holding
39
New
8
Increased
13
Reduced
2
Closed
16

Top Buys

Rank Stock Value
1
CFMS
Conformis, Inc. Common Stock
CFMS
+$14.6M
2
ADMA icon
ADMA Biologics
ADMA
+$13M
3
XERS icon
Xeris Biopharma Holdings
XERS
+$12.2M
4
EOLS icon
Evolus
EOLS
+$10.7M
5
OPTN
OptiNose
OPTN
+$8.58M

Top Sells

Rank Stock Value
1
ADMS
Adamas Pharmaceuticals
ADMS
+$19.2M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$12.8M
3
GYRE icon
Gyre Therapeutics
GYRE
+$10.8M
4
SBBP
Strongbridge Biopharma plc.
SBBP
+$9.16M
5
AFMD
Affimed
AFMD
+$7.18M

Sector Composition

Rank Sector Weight
1 Healthcare 94.84%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EYPT icon
26
EyePoint Inc
EYPT
$1.08B
– –
-80,537
Closed -$839K
LKFT
27
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
– –
-244,205
Closed -$12.8M
GYRE icon
28
Gyre Therapeutics
GYRE
$648M
– –
-351,335
Closed -$10.8M
IMUX icon
29
Immunic
IMUX
$191M
– –
-2,241
Closed -$198K
KALV
30
DELISTED
KalVista Pharmaceuticals
KALV
– –
-200,000
Closed -$3.49M
CYPH
31
Cypherpunk Technologies Inc
CYPH
$66.6M
– –
-25,000
Closed -$1M
SCYX icon
32
SCYNEXIS
SCYX
$37M
– –
-791
Closed -$34K
KA
33
DELISTED
Kineta, Inc. Common Stock
KA
– –
-68,813
Closed -$4.97M
NBSE
34
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
– –
-5,487
Closed -$396K
GMDA
35
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
– –
-1,724,201
Closed -$6.76M
SPNE
36
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
– –
-8,349
Closed -$131K
ADMS
37
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-3,914,938
Closed -$19.2M
SBBP
38
DELISTED
Strongbridge Biopharma plc.
SBBP
– –
-4,489,687
Closed -$9.16M
CFRX
39
DELISTED
ContraFect Corporation
CFRX
– –
-430
Closed -$139K
1
2

Similar funds

ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Stonepine Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Stonepine Capital Management held 39 positions worth $218M, down 0.84% from $220M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Stonepine Capital Management deployed $19.9M of net new capital in Q4 2021, opening 8 new positions and adding to 13 existing holdings. Its largest new stake was ADMA Biologics: 9,911,577 shares worth $14M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 90% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Celcuity, an estimated $884K trimmed.

  • Stonepine Capital Management's largest Q4 2021 buy was ADMA Biologics: 9,911,577 shares worth $14M.
  • Stonepine Capital Management added most to Conformis, Inc. Common Stock in Q4 2021, an estimated $14.6M increase.
  • Stonepine Capital Management's biggest Q4 2021 reduction was Celcuity, cutting an estimated $884K.
  • Stonepine Capital Management fully exited Adamas Pharmaceuticals in Q4 2021, selling an estimated $19.2M.
  • Stonepine Capital Management's ten largest holdings make up 84% of its $218M portfolio in Q4 2021.
  • Stonepine Capital Management opened 8 new positions and closed 16 in Q4 2021.
  • Stonepine Capital Management's portfolio value fell 0.84% quarter-over-quarter to $218M.

Based on Stonepine Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.